Pipeline Sustainability Inspire emphasizes a sustainable, multi asset ophthalmic and pulmonary portfolio with candidates advancing toward potential regulatory approval, signaling long term partnership opportunities.

Ophthalmic Growth Key near term sales potential exists with AZASITE for blepharitis and PROLACRIA for dry eye, offering chances to expand in ophthalmology networks and drive territory based promotions.

Revenue Diversification A diversified revenue model, including AZASITE product sales, ELESTAT co-promotion, and RESTASIS royalties, provides multiple entry points for clinician outreach and payer discussions.

Mid Size Agility Mid size company footprint enables targeted, efficient field teams to engage eye care providers, optimize regional launches, and build partner focused sales programs.

Market Growth Growing dry eye and ocular surface disease markets create upside for sales development through strategic partnerships, physician education programs, and leverage of existing royalty and co promotion channels.